The association between the immune status within the tumor microenvironment and prognosis in synovial sarcoma is not well understood. We aimed to investigate the tumor immune microenvironment and analyze its prognostic impact for patients with synovial sarcoma. A total of 36 primary patients who were treated in our institution were retrospectively evaluated. Infiltration of lymphocytes (CD4+, CD8+, and FOXP3+), CD163+ macrophages, and expression of human leukocyte antigen (HLA) class I and programmed death ligand 1 (PD-L1) were evaluated by immunohistochemistry. Moreover, we investigated PD-L1 and programmed death ligand 2 (PD-L2) mRNA expression in 19 of the 36 cases, using real-time PCR. The Kaplan-Meier method was used to estimate overall survival and progression-free survival. Infiltration of lymphocytes and macrophages varied among the patients. Furthermore, the expression of HLA class I was negative or downregulated in 11 specimens. No PD-L1 expression was observed using immunohistochemistry. Moreover, although PD-L1 mRNA expression was observed in 18 of 19 specimens, the expression level was low. A higher infiltration of CD8+ or FOXP3+ lymphocytes in patients was associated with a favorable overall survival. In addition, a higher infiltration of CD163+ macrophages indicated a significantly worse overall and progression-free survival. Infiltration of CD4+ lymphocytes, HLA class I, PD-L1, and PD-L2 expression were not associated with patient prognosis. This represents the first report investigating the tumor immune microenvironment as a prognostic factor in synovial sarcoma, indicating that CD163+ macrophages are associated with tumor progression. Our results underscore the clinical significance of the tumor immune microenvironment in synovial sarcoma.
76%.
1,2 Standard treatment for primary localized SS consists of surgery, radiotherapy, and chemotherapy. However, local or metastatic recurrences occur in approximately 50% of patients at 5 years, 3 and the benefit of adjuvant chemotherapy in localized primary SS cases is still controversial. 2 In addition, the prognosis of metastatic or relapsed SS remains poor. Thus, to improve the survival rate of patients with SS, the development of novel therapies is needed.
Synovial sarcoma presents a specific chromosomal translocation t (X:18) (p11.2;q11.2), resulting in SS18-SSX1 or SS18-SSX2, and rarely into the SS18-SSX4 fusion proteins. 4, 5 Moreover, the NY-ESO-1 cancer testis antigen is expressed in approximately 80% of SS cases. 6, 7 Recently, immunotherapies consisting of SYT-SSX or NY-ESO-1-delivered peptide vaccines 8, 9 or autologous T cells transduced with a T-cell receptor directed against NY-ESO-1 were attempted for patients with SS. 10 Importantly, clinical trials using an adoptive cell transfer of autologous T cells transduced with anti-NY-ESO-1 have
shown promise in triggering objective responses in patients with metastatic or refractory disease. 10 These data suggest that immunotherapies may be effective in the treatment of SS.
Programmed cell death 1 and its ligands, PD-L1 and PD-L2, play a key role in the immune escape of tumor cells by inactivating T-cell function. Several authors have shown that antibodies blocking PD-1 or PD-L1 lead to improved clinical outcomes in a variety of malignancies. [11] [12] [13] However, previous reports have indicated that expression of PD-L1/ PD-L2 has different prognostic value in various cancers. [14] [15] [16] [17] Association between PD-L1 expression and the prognosis of soft tissue sarcoma, including SS, was also examined. However, because these studies comprised a small number of patients with SS, the expression of PD-L1 in SS and its clinical significance remain controversial. [17] [18] [19] [20] [21] Understanding how the tumor immune microenvironment relates 
| MATERIALS AND METHODS

| Patient tissue samples
A total of 39 primary patients with SS, who were diagnosed and treated in Niigata University Hospital and Niigata Cancer Center Hospital between 1983 and 2017, were enrolled. To evaluate the natural tumor immune microenvironment, three patients were excluded because they had already received some treatment in other hospitals or for which specimens without neoadjuvant chemotherapy were not available. Thus, a total of 36 patients were retrospectively examined in this study. We used biopsy specimens for the immunohistochemical examination if the patient had received neoadjuvant chemotherapy. In any other case, we used surgical specimens for the examination. In all cases, H&E staining was prepared from the archives. The SS diagnosis was confirmed and representative samples, including viable tumor cells, were selected by an experienced pathologist. The patient's clinical information and follow-up data were collected from the medical records for statistical analysis. Clinical characteristics of the patients are summarized in Table 1. There were 23 male and 13 female patients with a mean age of 36 years (ranging from 10 to 76 years).
Three of these patients showed lung metastasis at diagnosis. Ten tumors were located in the upper extremities, 23 in the lower extremities, and three in the trunk. The American Joint Committee on Cancer (AJCC) 7th edition staging system was used to classify disease staging; 22 
| Evaluation of immunohistochemistry
For TILs and macrophages, tumor sections were evaluated at low magnification, and the areas with the most abundant TILs or macrophages were selected. A maximum of five high-power fields (×200) was then digitally photographed in a size of 0.093 mm 2 with an Olympus DP73 digital camera (Olympus, Tokyo, Japan) and counted manually. The count was conducted two times by an experienced pathologist who was blinded to previously available results and clinical information. Average value in an area of 1 mm 2 was used for the statistical analysis. For each immunohistochemical marker, we divided the patients into subgroups. The patients were classified into "high" and "low" infiltration groups except for HLA class I, where the "high" group displayed a number of TILs or macrophages that was above the median. For HLA class I, we classified the 36 cases into high (number of positive cells >50%), low (number of positive cells <50%), and negative (the samples were negative for these cells). For PD-L1, the patients were assigned to the "high" group when the number of positive cells >1%, as previously reported. mRNA expression levels in each sample were normalized by the GAPDH levels. Gene copy number for PD-L1 was calculated using a standard curve that was constructed using the MDA-MB-231 cell line. MDA-MB-231 was previously reported as a positive control and was used as a calibrator. 23 Nineteen patients were divided into two subgroups for the statistical analysis. The patients were considered as belonging to the "high" group when the PD-L1 or PD-L2 mRNA level was above the median, and the levels for the rest of the patients were low.
| Western blot analysis
HS-SYII and SYO-1 were subjected to western blot analysis to assess endogenous expression of the PD-L1 protein as previously reported. 26 Briefly, the cells were suspended in a sample buffer con- | 3045 at room temperature. Bands were visualized by ECL detection reagents (GE Healthcare). abilities and survival differences were analyzed using the log-rank test.
| Statistical analysis
Multivariate analysis was conducted using the COX proportional hazard model. P-value < 0.05 was considered statistically significant.
| RESULTS
| Clinical course of the patients
Mean follow-up times were 112.7 months (6-366 months). OS probabilities of the 36 patients with SS at 5 and 10 years were 82.7%
and 75.2%, respectively. The 5 and 10-year PFS probabilities were both 67.5%. Local recurrence was observed in one case and 12 patients developed distant metastasis. Sites of distant metastasis were the lung in 10 patients, and the lymph nodes, kidney, and vertebra in one patient.
| Infiltration of lymphocytes and macrophages
Representative images displaying high or low levels of infiltration for CD8+, FOXP3+ lymphocytes, or CD163+ macrophages are shown in Figure 1 . Figure 2 shows the number of CD4+, CD8+, and FOXP3+ TILs, and CD163+ macrophages that infiltrated into the tumor per mm 2 . Although CD163+ macrophages were seen in all patients, 10 patients were negative for CD4, one patient was negative for CD8, and nine patients were negative for FOXP3. 
| Expression of HLA class I and PD-L1
Immunohistochemical staining for HLA class I was conducted and 
| DISCUSSION
Some studies have examined the tumor microenvironment, including infiltration of CD8+ lymphocytes and expression of PD-L1 in soft tissue sarcomas. 18, 21, 27 However, those studies often lump together heterogeneous types of soft tissue sarcomas and include limited numbers of patients with SS. To the best of our knowledge, the present study is the first report to focus on the tumor immune environment in patients with SS. We investigated the tumor immune microenvironment including infiltration of CD4+, CD8+, and Although present study used a median value as the cutoff, Que et al defined "high infiltration" as infiltration occurring in greater than 5% sive adaptive immunity, tumor cell proliferation, and metastasis. 37, 38 CD163 is considered a marker for M2-like macrophages and a high number of infiltrating CD163+ macrophages represents a poor prognostic predictor in several cancers. [38] [39] [40] However, the prognostic impact of CD163+ macrophages in patients with SS is still unknown.
To our knowledge, this is the first report that has examined the association between the infiltration of CD163+ macrophages and SS prognosis in a patient cohort. In the present study, we showed that a higher infiltration of CD163+ macrophages was associated with poor prognosis and the progression of SS. This suggests that CD163+ macrophages might play a key role in the progression of the disease in patients with SS, more so than PD-L1. Indeed, although a case report discussed the efficacy of PD-1 blockade therapy in advanced sarcoma, 41 the efficacy of a therapy targeting PD-1 in soft tissue sarcoma is limited. 42 The present study has several limitations. First, as this was a retrospective study, the patient's baseline characteristics varied. Thus, this study comprises patients with distant metastasis at diagnosis, and this might have influenced our results. To confirm these results, further studies are needed to evaluate a greater number of tumor specimens with a similar presentation status. Moreover, the evaluation of metastatic specimens was beyond the scope of our study, and we could not address the tumor immune microenvironment in metastatic tumors.
Finally, we evaluated the expression of PD-L1 using one antibody only.
Therefore, our results could be influenced by the antibody used. To remedy this problem, a standardized method for testing the expression of PD-L1 using immunohistochemistry is required.
In conclusion, we showed that PD-L1 was not expressed in any of the patients, as assessed by immunohistochemistry, and that the PD-L1 mRNA expression level was low in the tumor microenvironment of patients with SS. In addition, our results showed that a lower infiltration of CD8+ and FOXP3+ lymphocytes and a higher infiltration of CD163+ macrophages were associated with an unfavorable prognosis in patients with SS. We also showed that the infiltration of CD163+ macrophages might play an important role in disease progression in patients with SS. We believe these data offer novel insights into the SS tumor immune microenvironment and will provide a foundation for developing immunotherapies for patients with SS.
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